WO2001056548A3 - Liposomes composition produced by a dehydration-rehydration process - Google Patents

Liposomes composition produced by a dehydration-rehydration process Download PDF

Info

Publication number
WO2001056548A3
WO2001056548A3 PCT/GB2001/000391 GB0100391W WO0156548A3 WO 2001056548 A3 WO2001056548 A3 WO 2001056548A3 GB 0100391 W GB0100391 W GB 0100391W WO 0156548 A3 WO0156548 A3 WO 0156548A3
Authority
WO
WIPO (PCT)
Prior art keywords
dehydration
sugar
lipid
liposomes
composition produced
Prior art date
Application number
PCT/GB2001/000391
Other languages
French (fr)
Other versions
WO2001056548A2 (en
Inventor
Brahim Zadi
Original Assignee
Lipoxen Technologies Ltd
Brahim Zadi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipoxen Technologies Ltd, Brahim Zadi filed Critical Lipoxen Technologies Ltd
Priority to AU28699/01A priority Critical patent/AU2869901A/en
Priority to DE60123583T priority patent/DE60123583T2/en
Priority to JP2001556240A priority patent/JP4786105B2/en
Priority to EP01948934A priority patent/EP1259225B1/en
Priority to US10/182,921 priority patent/US7025988B2/en
Publication of WO2001056548A2 publication Critical patent/WO2001056548A2/en
Publication of WO2001056548A3 publication Critical patent/WO2001056548A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

Liposomes containing lipophilic active ingredient are produced by dehydrating a mixture of liposomes, lipophilic active ingredient and sugar, usually followed by a rehydration step to form dehydration-rehydration vesicles. The lipophilic drug is suitably paclitaxel. The sugar is usually sucrose. The liposome forming compounds preferably include cholesterol and phosphatidylcholine, and optionally an anionic lipid. The ratio of sugar:lipid is preferably at least 5:1 w/w. The ratio of lipid:drug is preferably (up to 10):1 w/w.
PCT/GB2001/000391 2000-02-04 2001-01-31 Liposomes composition produced by a dehydration-rehydration process WO2001056548A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU28699/01A AU2869901A (en) 2000-02-04 2001-01-31 Liposomes
DE60123583T DE60123583T2 (en) 2000-02-04 2001-01-31 DEHYDRATISATION / REHYDRATISATION PROCESS FOR THE PREPARATION OF LIPOSOME
JP2001556240A JP4786105B2 (en) 2000-02-04 2001-01-31 Liposome
EP01948934A EP1259225B1 (en) 2000-02-04 2001-01-31 Process of dehydration/rehydration for making liposomes
US10/182,921 US7025988B2 (en) 2000-02-04 2001-01-31 Liposomes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00300904.0 2000-02-04
EP00300904 2000-02-04

Publications (2)

Publication Number Publication Date
WO2001056548A2 WO2001056548A2 (en) 2001-08-09
WO2001056548A3 true WO2001056548A3 (en) 2002-03-21

Family

ID=8172682

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/000391 WO2001056548A2 (en) 2000-02-04 2001-01-31 Liposomes composition produced by a dehydration-rehydration process

Country Status (8)

Country Link
US (1) US7025988B2 (en)
EP (1) EP1259225B1 (en)
JP (1) JP4786105B2 (en)
AT (1) ATE341310T1 (en)
AU (1) AU2869901A (en)
DE (1) DE60123583T2 (en)
ES (1) ES2272496T3 (en)
WO (1) WO2001056548A2 (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502653A (en) * 2001-08-20 2005-01-27 トランセーヴ・インコーポレーテッド How to treat lung cancer
PT1509256E (en) 2002-05-24 2009-10-15 Angiotech Int Ag Compositions and methods for coating medical implants
CA2491216C (en) 2002-06-26 2012-01-03 Medigene Oncology Gmbh Method of producing a cationic liposomal preparation comprising a lipophilic compound
EP1519745B1 (en) 2002-07-05 2006-12-20 Lipoxen Technologies Limited Method to enhance an immune response of nucleic acid vaccination
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
KR20050038011A (en) * 2002-08-02 2005-04-25 트랜세이브, 인코포레이티드 Platinum aggregates and process for producing the same
CN100518831C (en) * 2002-08-15 2009-07-29 刘云清 Solid nano-medicine and preparing method thereof
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
BRPI0407415A (en) * 2003-02-11 2006-01-10 Neopharm Inc Method of making a liposome preparation
JP2007522085A (en) * 2003-06-27 2007-08-09 スミスクライン・ビーチャム・コーポレイション Stabilized topotecan liposome compositions and methods
US20050048109A1 (en) * 2003-08-26 2005-03-03 Ceramoptec Industries, Inc. Non-polar photosensitizer formulations for photodynamic therapy
EP1729786A4 (en) * 2004-03-18 2008-03-26 Transave Inc Administration of cisplatin by inhalation
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
KR101462825B1 (en) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 Liposomes useful for drug delivery
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
WO2005112957A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
US20050281799A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting damaged lung tissue using compositions
US7553810B2 (en) * 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US20050281798A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting sites of damaged lung tissue using composition
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US20050281739A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue using compositions
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US7608579B2 (en) * 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US7766938B2 (en) 2004-07-08 2010-08-03 Pneumrx, Inc. Pleural effusion treatment device, method and material
KR20070089693A (en) * 2004-11-08 2007-08-31 트랜세이브, 인코포레이티드 Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
JP5303269B2 (en) 2005-06-06 2013-10-02 学校法人早稲田大学 Bone marrow-directed drug delivery materials and uses thereof
TWI291237B (en) * 2005-10-07 2007-12-11 Integrated Digital Technologie Photo detector array
WO2007056236A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
PL1962805T3 (en) 2005-12-08 2017-01-31 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
ES2668554T3 (en) * 2006-04-06 2018-05-18 Insmed Incorporated Methods for coacervation-induced liposomal encapsulation and its formulations
WO2008036763A2 (en) * 2006-09-20 2008-03-27 Pneumrx, Inc. Tissue adhesive compositions and methods thereof
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9445975B2 (en) 2008-10-03 2016-09-20 Access Business Group International, Llc Composition and method for preparing stable unilamellar liposomal suspension
CA2734284C (en) * 2008-11-20 2014-01-21 Techno Guard Co., Ltd. Pyrazolone derivative formulations
US8591942B2 (en) * 2009-09-23 2013-11-26 Indu JAVERI Methods for the preparation of liposomes comprising docetaxel
US20110070294A1 (en) * 2009-09-23 2011-03-24 Javeri Indu Methods for the Administration of Drugs Using Liposomes
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
EP2394640A1 (en) * 2010-05-21 2011-12-14 MediGene AG Improved liposomal formulations of lipophilic compounds
JP6402097B2 (en) 2012-05-21 2018-10-10 インスメッド インコーポレイテッド System for treating pulmonary infections
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
EP2682106A1 (en) 2012-07-03 2014-01-08 Phares Pharmaceutical Research N.V. Method of solubilizing biologically active compounds
WO2014034669A1 (en) * 2012-08-28 2014-03-06 国立大学法人北海道大学 Lipid membrane structure including bacterial cell component having dispersibility in non-polar solvent, and method for producing same
JP2015530387A (en) 2012-09-04 2015-10-15 エライゾン ファーマシューティカルズ， エルエルシー Prevention of recurrence of lung cancer by lipid complexed cisplatin
ES2743039T3 (en) 2012-11-29 2020-02-18 Insmed Inc Vancomycin stabilized formulations
US10238675B2 (en) 2014-05-15 2019-03-26 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
RU2760185C2 (en) 2015-08-20 2021-11-22 Ипсен Биофарм Лтд. Combination therapy using liposomal irinotecan and parp inhibitor for the treatment of cancer
WO2017034957A1 (en) 2015-08-21 2017-03-02 Merrimack Pharmaceuticals, Inc. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
EP3362049A1 (en) 2015-10-16 2018-08-22 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
CN106924195B (en) * 2015-12-31 2020-11-13 南京绿叶制药有限公司 Freeze-drying process of paclitaxel liposome composition for injection
MY198105A (en) * 2016-01-07 2023-08-02 Univ Western Health Sciences Formulations for treating bladder cancer
AU2017351900B2 (en) * 2016-10-31 2020-11-26 Eyegene Inc. Composition for enhancing immunity comprising immune modulator and cationic liposome, and use of same
SG10201912338RA (en) 2016-11-02 2020-02-27 Ipsen Biopharm Ltd Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001103A1 (en) * 1984-08-08 1986-02-27 The Liposome Company, Inc. Dehydrated liposomes
WO1987001933A1 (en) * 1985-09-27 1987-04-09 Liposome Technology, Inc. Stabilized liposome/amphotericin composition and method
US4885172A (en) * 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
EP0700679A1 (en) * 1994-09-12 1996-03-13 Bayer Ag Injectable liposomal compositions
US5683715A (en) * 1993-05-17 1997-11-04 The Liposome Company, Inc. Taxane-containing phosphatidylcholine liposomes
WO1999065465A1 (en) * 1998-06-18 1999-12-23 The Secretary Of State For Defence Method of forming liposomes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593394A1 (en) * 1986-01-30 1987-07-31 Ire Celltarg Sa Method for preparing liposomes containing a lipophilic active substance, in particular amphotericin, and liposomes and new medicament which are obtained
GB9320668D0 (en) * 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
EP0792143B1 (en) * 1994-11-18 2002-09-04 Aphios Corporation Methods for making liposomes containing hydrophobic drugs
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001103A1 (en) * 1984-08-08 1986-02-27 The Liposome Company, Inc. Dehydrated liposomes
US4885172A (en) * 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
WO1987001933A1 (en) * 1985-09-27 1987-04-09 Liposome Technology, Inc. Stabilized liposome/amphotericin composition and method
US5683715A (en) * 1993-05-17 1997-11-04 The Liposome Company, Inc. Taxane-containing phosphatidylcholine liposomes
EP0700679A1 (en) * 1994-09-12 1996-03-13 Bayer Ag Injectable liposomal compositions
WO1999065465A1 (en) * 1998-06-18 1999-12-23 The Secretary Of State For Defence Method of forming liposomes

Also Published As

Publication number Publication date
DE60123583T2 (en) 2007-08-09
AU2869901A (en) 2001-08-14
JP4786105B2 (en) 2011-10-05
ATE341310T1 (en) 2006-10-15
ES2272496T3 (en) 2007-05-01
US7025988B2 (en) 2006-04-11
JP2003521508A (en) 2003-07-15
US20030138481A1 (en) 2003-07-24
DE60123583D1 (en) 2006-11-16
WO2001056548A2 (en) 2001-08-09
EP1259225B1 (en) 2006-10-04
EP1259225A2 (en) 2002-11-27

Similar Documents

Publication Publication Date Title
WO2001056548A3 (en) Liposomes composition produced by a dehydration-rehydration process
EP0277776A3 (en) Solid core liposomes
TW359616B (en) A parenterally administered pharmaceutical composition for lipophilic, poorly soluble active compounds, in the form of liposomes with phospholipid membranes
NZ334561A (en) Preparation of multivesicular liposomes for controPreparation of multivesicular liposomes for controlled release of active agents lled release of active agents
AU8141891A (en) Unilamellar vesicles
WO1999016426A3 (en) Multilamellar coalescence vesicles (mlcv) containing biologically active compounds
WO2000065024A3 (en) Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules
WO2002000201A3 (en) Method for preparing a composition
AU6036596A (en) Process for making liposome preparation
AU7407994A (en) Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
JP2003513003A5 (en)
NZ508960A (en) Method of forming liposomes
WO2002076427A3 (en) Ph sensitive liposomal drug delivery
EP2108362A3 (en) Method of producing a cationic liposomal preparation comprising a lipophilic compound
NZ503293A (en) Liposomal camptothecin formulations also comprising at least one phospholipid
CA2376849A1 (en) Method of inhibiting leakage of drug encapsulated in liposomes
ES2086802T3 (en) LIPOSOMIC FORMULATIONS OF ACTIVE PRINCIPLES AND PROCEDURE FOR THE PREPARATION.
CA2346016A1 (en) Glucoside paucilamellar vesicles
EP0198765A3 (en) Preparation of liposomes
CA2488124A1 (en) Vitamin a liposomes and the method of its preparation
CA2177696A1 (en) Lipid vesicles containing avocado oil unsaponifiables
HUT62457A (en) Process for producing aqueous liposomal suspensions comprising an active ingredient
WO2002048380A3 (en) Glycosilated cationic lipids for liposomes used in drug delivery
WO2003026617A3 (en) (ester)-lysolecithins in liposomes
WO1999049716A3 (en) Method for producing liposomal formulations of active agents by high-pressure homogenisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001948934

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 556240

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10182921

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001948934

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001948934

Country of ref document: EP